These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 24670527)
1. Occurrence of etravirine/rilpivirine-specific resistance mutations selected by efavirenz and nevirapine in Kenyan patients with non-B HIV-1 subtypes failing antiretroviral therapy. Crawford KW; Njeru D; Maswai J; Omondi M; Apollo D; Kimetto J; Gitonga L; Munyao J; Langat R; Aoko A; Tarus J; Khamadi S; Hamm TE AIDS; 2014 Jan; 28(3):442-5. PubMed ID: 24670527 [TBL] [Abstract][Full Text] [Related]
2. Short communication: east meets west: a description of HIV-1 drug resistance mutation patterns of patients failing first line therapy in PEPFAR clinics from Uganda and Nigeria. Crawford KW; Wakabi S; Kibuuka H; Magala F; Keshinro B; Okoye I; Akintunde E; Hamm TE AIDS Res Hum Retroviruses; 2014 Aug; 30(8):796-9. PubMed ID: 24798614 [TBL] [Abstract][Full Text] [Related]
3. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine. Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807 [TBL] [Abstract][Full Text] [Related]
6. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076 [TBL] [Abstract][Full Text] [Related]
7. Etravirine and rilpivirine-specific mutations selected by efavirenz and nevirapine exposure in patients infected with HIV-1 non-B subtypes. Crawford KW AIDS; 2014 Sep; 28(15):2331-2. PubMed ID: 25050862 [No Abstract] [Full Text] [Related]
8. Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine. Theys K; Camacho RJ; Gomes P; Vandamme AM; Rhee SY; Clin Microbiol Infect; 2015 Jun; 21(6):607.e1-8. PubMed ID: 25704446 [TBL] [Abstract][Full Text] [Related]
9. HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors. Ghosn J; Chaix ML; Delaugerre C AIDS Rev; 2009; 11(3):165-73. PubMed ID: 19654858 [TBL] [Abstract][Full Text] [Related]
10. Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana. Diphoko T; Gaseitsiwe S; Kasvosve I; Moyo S; Okatch H; Musonda R; Wainberg M; Makhema J; Marlink R; Novitsky V; Essex M AIDS Res Hum Retroviruses; 2018 Aug; 34(8):667-671. PubMed ID: 29732907 [TBL] [Abstract][Full Text] [Related]
11. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa. van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793 [TBL] [Abstract][Full Text] [Related]
12. Genetic barrier to the development of resistance to rilpivirine and etravirine between HIV-1 subtypes CRF02_AG and B. Fofana DB; Soulie C; Maiga AI; Fourati S; Malet I; Wirden M; Tounkara A; Traore HA; Calvez V; Marcelin AG; Lambert-Niclot S J Antimicrob Chemother; 2013 Nov; 68(11):2515-20. PubMed ID: 23833185 [TBL] [Abstract][Full Text] [Related]
19. Etravirine and Rilpivirine Drug Resistance Among HIV-1 Subtype C Infected Children Failing Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens in South India. Saravanan S; Kausalya B; Gomathi S; Sivamalar S; Pachamuthu B; Selvamuthu P; Pradeep A; Sunil S; Mothi SN; Smith DM; Kantor R AIDS Res Hum Retroviruses; 2017 Jun; 33(6):567-574. PubMed ID: 27869478 [TBL] [Abstract][Full Text] [Related]